ClinicalTrials.gg
CompletedNCT06511869Updated Jul 4, 2025

AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

A Phase 2 interventional study of AZD4205 in Peripheral T-cell Lymphoma, sponsored by Dizal Pharmaceuticals. Completed at 23 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by Dizal Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Mar 2022, registered Jul 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing golidocitinib in Lymphoma, T-Cell, Peripheral — 13 open to participants now, 13 under way, 3 of them phase 3. golidocitinib · Lymphoma, T-Cell, Peripheral.

Enrollment
9th of 16
48 · median 53
Started
2022
with 1 other
Phase 2
7 of 16
5 open now
Registered
3rd of 16
by date
Lead sponsor
4 of 16
Dizal Pharmaceuticals

Among the 16 studies testing golidocitinib in Lymphoma, T-Cell, Peripheral, this one is the 9th largest by enrollment, is one of 2 that started in 2022, is one of 7 in phase 2, and was the 3rd registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

13 of the 16 studies testing golidocitinib in Lymphoma, T-Cell, Peripheral are open now, in 4 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About golidocitinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing golidocitinib in Lymphoma, T-Cell, Peripheral, or all of them as a file.
02

Study summary

This study is intended to assess the safety and anti-tumor activity of AZD4205 at 150 mg once daily in participants with PTCL who have achieved tumor response after first-line systemic therapy (with or without combination radiotherapy) and are ineligible for HSCT assessed by the investigator as ineligible for HSCT or have no plan for HSCT.

03

Conditions studied

  • Peripheral T-cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years old.
  2. status score ranging from 0 to 1, without any deterioration in the past two weeks.
  3. ≥ 3 months.
  4. Have histopathologically confirmed PTCL that meets the pathological subtypes (except for ALCL-ALK+) as specified in the latest WHO classification of lymphoid neoplasms in 2016.
  5. Must be assessed to achieve complete or partial response according to Lugano's criteria after systemic standard of therapy:

    • The participants should be assessed as ineligible for
    • For participants with CR, the end of initial treatment should be ≤ 3 months from the planned first dose in this study.
  6. Adequate bone marrow hematopoietic function and organ function reserve.
  7. ≥ 50% by ECHO.
  8. Should be able to follow the relevant requirements of this study for medication and follow-up.
  9. If there is a potential for conception for the female spouses (partners) of male participants, the spouses (partners) should take physical measures (such as condoms) during the participant participating in the trial and within 6 months after the end of treatment.
  10. Male participants should also avoid sperm donation during the trial and within 6 months after the end of treatment.
  11. Female participants should take adequate contraceptive measures and vasoligation of the partner during the trial and within 3 months after the end of the trial. All hormonal contraceptive methods (except abstinence) should be used in conjunction with the use of a condom by the male partner. Breastfeeding is prohibited for female participants. Female participants of conception potential should have a negative pregnancy test prior to initiation of treatment.

Exclusion criteria

Exclusion criteria

  1. With any of the following treatment history:

    • The use of the product or investigational product in another project within 30 days prior to the start of dosing in this study.
    • The cytotoxic chemotherapeutic agents are not discontinued within 21 days prior to the start of dosing in this study.
    • Prior use of histone deacetylase (HDAC) inhibitors (e.g., romidepsin, chidamide, belinostat) or pralatrexate within 1 week prior to the start of dosing in this study.
    • Prior use of therapy at equivalent prednisone dose > 15 mg/day within 1 week prior to the start of dosing in this study.
    • Undergoing major surgery (excluding vascular access surgery) or serious trauma within 4 weeks prior to the start of dosing in this study; or anticipated to undergo potential surgery after the start of dosing in this study.
    • Prior use of anti-tumor macromolecular antibody agents (including brentuximab vedotin) within 4 weeks; radiation therapy within 3 weeks; and other toxin/isotope-immune antibody couplers within 10 weeks prior to the start of dosing in this study.
    • With prior use of JAK or STAT3 inhibitors.
    • Prior use of anti-tumor immunotherapy (e.g., , including PD-1, PD-L1, and CTLA-4) within 28 days prior to the start of dosing in this study. For participants treated with other types of novel therapy, whether they can be included may be jointly decided by the investigator and the sponsor's study physician.
    • Vaccination with attenuated vaccines or viral vector vaccines within 28 days prior to the start of dosing in this study.
    • Currently on treatment with vitamin K antagonists, antiplatelets, and anticoagulants (or these drugs cannot be discontinued within 1 week prior to the start of dosing in this study).
    • Currently on treatment with (or unable to discontinue the use within 1 week prior to the start of dosing in this study) certain known drugs, herbs, or supplements that may significantly induce or inhibit or can serve as sensitive substrates of BCRP/P-gp, with low therapeutic indexes.
  2. With unresolved > Grade 1 adverse drug reactions (except alopecia) prior to the start of dosing in this study.
  3. Central nervous system or meninges involvement by the lymphoma.
  4. With significant lung function impairment (i.e., pulmonary function tests show and DLCO \< 60% of predicted values). Participants with prior history of non-infectious pneumonitis, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy, or evidence showing clinically active interstitial lung disease.
  5. With diseases or conditions requiring treatment with agents, similar biological agents, or non-steroidal analgesic-antipyretic drugs.
  6. Active infection, including:

    • Known active/latent tuberculosis (screening should be performed according to the routine procedures of local clinical sites, such as PPD test, T-SPOT, and X-ray/CT).
    • With positive test or serological hepatitis markers.
    • Active viral infections (e.g., herpes zoster) other than or .
    • Infections requiring oral or intravenous antimicrobial therapy.
    • Bacterial infection within 30 days, including pneumonia.
  7. Any of the following cardiac abnormalities:

    • With congestive heart failure (CHF) > Class II.
    • With significant clinical manifestations of valvular disease and hypertrophic/constrictive cardiomyopathy.
    • With serious cardiac rhythm, conduction, morphological abnormalities on any resting , such as complete left bundle branch block, 2/3-degree atrioventricular block, and PR interval > 250 ms.
    • Ventricular arrhythmia requiring treatment.
    • Acute myocardial infarction (AMI) within 6 months prior to the start of treatment in the trial; unstable angina pectoris or new angina pectoris.
    • Who have undergone heart transplantation.
    • Corrected interval (QTc) > 450 ms on resting ECG at screening.
    • With increased risks of QT prolongation or arrhythmia (e.g., heart failure, hypokalemia, congenital long QT syndrome, or taking other drugs causing QT prolongation; or with a family history of long QT syndrome; or those with first-degree relatives showing unexpected sudden death under 40 years of age.
    • Prior or current history of thrombotic diseases such as pulmonary embolism and deep vein thrombosis.
  8. Prior history of (except completely eradicated cervical, uterine, basal cell, or squamous cell carcinoma in situ, or non-melanoma skin carcinoma in situ) within 5 years prior to enrollment.
  9. With symptoms of intractable nausea or vomiting that cannot be well controlled with supportive treatment, chronic gastrointestinal disease, capsule dysphagia, or prior surgical removal of bowel segments that may compromise adequate absorption of the drug.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    AZD4205 treatment

    Cohort 1: Participants achieving a CR as assessed by the investigator according to Lugano criteria following the first-line systemic therapy. Cohort 2: Participants achieving a PR as assessed by the investigator according to Lugano criteria following the first-line systemic therapy.

    Drug: AZD4205

Interventions

  • AZD4205 capsules administered at 150 mg orally, once daily, in 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Adverse events and serious adverse events (graded by CTCAE version 5.0)

    To assess the safety and tolerability of AZD4205 as maintenance/consolidation therapy in PTCL participants achieving tumor response after first-line systemic therapy

    Time frame: up to 2 years

Secondary outcomes

  1. Cohort 1: Disease Free Survival (DFS)

    To assess the anti-tumor activity of AZD4205 as maintenance/consolidation therapy in PTCL participants achieving tumor response after first-line systemic therapy

    Time frame: up to 2 years

  2. Cohort 1: Disease Free Survival (DFS) rate at 1 year from the first dose of investigational product

    To assess the anti-tumor activity of AZD4205 as maintenance/consolidation therapy in PTCL participants achieving tumor response after first-line systemic therapy

    Time frame: 1 year

  3. Cohort 2: Objective Response Rate (ORR)

    To assess the anti-tumor activity of AZD4205 as maintenance/consolidation therapy in PTCL participants achieving tumor response after first-line systemic therapy

    Time frame: up to 2 years

  4. Cohort 2: Duration of Response (DoR)

    To assess the anti-tumor activity of AZD4205 as maintenance/consolidation therapy in PTCL participants achieving tumor response after first-line systemic therapy

    Time frame: up to 2 years

  5. Cohort 2: Progression-free Survival (PFS)

    To assess the anti-tumor activity of AZD4205 as maintenance/consolidation therapy in PTCL participants achieving tumor response after first-line systemic therapy

    Time frame: up to 2 years

  6. Cohort 2: Progression-free Survival (PFS) rate at 1 year from the first dose of investigational product

    To assess the anti-tumor activity of AZD4205 as maintenance/consolidation therapy in PTCL participants achieving tumor response after first-line systemic therapy

    Time frame: 1 year

07

Study locations

23 sites
  • Anhui Provincial Hospital (The First Affiliated Hospital of USTC)
    Hefei, Anhui, China
  • Peking university Third Hospital
    Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
  • The Fifth Affiliated Hospital of Sun Yat-sen University
    Zhuhai, Guangdong, China
  • Hainan General Hospital
    Haikou, Hainan, China
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Hubei Cancer Hospital
    Wuhan, Hubei, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • Research Center of Clinical Trials, The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • Shandong Cancer Hospital & Institution
    Jinan, Shandong, China
  • Linyi Cancer Hospital
    Linyi, Shandong, China
  • Shanxi Provincial Cancer Hospital
    Taiyuan, Shanxi, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin Municipality, China
  • Yunnan Cancer Hospital
    Kunming, Yunnan, China
  • The First Affiliated Hospital, College of Medicine, Zhejiang University
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Mar 2025, 36 months.

Of 64 phase 2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 96. This study's 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jul 22, 2024
StartActual
Mar 17, 2022
Primary completionActual
Mar 31, 2025
CompletionActual
Mar 31, 2025
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06511869
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Mar 17, 2022
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025
Last update
Jul 4, 2025

Study contacts

Jie Jin
principal investigator · First Affiliated Hospital of Zhejiang University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golidocitinib

Start the discussion